Tivantinib is a selective oral inhibitor of MET that has now been tested in a phase II trial in patients with unresectable hepatocellular carcinoma. Compared with the placebo control, treatment with tivantinib significantly benefitted patients whose disease had progressed on first-line therapy, especially those patients who were determined to be MET positive by immunohistochemical analysis. A manageable safety profile was reported.
ORIGINAL RESEARCH PAPER
Rimassa, L. et al. Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT). J. Clin. Oncol. 30 (Suppl.), a4006 (2012)
Rights and permissions
About this article
Cite this article
Tivantinib shows promise in hepatocellular carcinoma. Nat Rev Clin Oncol 9, 428 (2012). https://doi.org/10.1038/nrclinonc.2012.110
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.110